Absci (NASDAQ:ABSI) Posts Quarterly Earnings Results

Absci (NASDAQ:ABSI) announced its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02), FiscalAI reports. The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.89 million. Absci had a negative return on equity of 66.32% and a negative net margin of 6,450.76%.

Here are the key takeaways from Absci’s conference call:

• ABS-201 interim Phase 1 results were encouraging: Management reported favorable safety and tolerability, with an estimated half-life of at least 65 days and modeling suggesting two to three doses could maintain more than 90% prolactin-receptor occupancy over six months.
• Multiple upcoming clinical catalysts remain on schedule. The company expects interim 13-week proof-of-concept data for pattern hair loss later in 2026, full 26-week data in early 2027, and plans to initiate a Phase 2 endometriosis study in the fourth quarter of 2026.
• Eli Lilly partnership and new financing strengthen resources. Lilly invested $40 million and is collaborating on ABS-201’s clinical development, while Absci’s June financing generated approximately $93.6 million in net proceeds and extended projected funding into the second half of 2028.
• Absci is expanding its AI drug-discovery platform with Atlas, which integrates literature, genetics, and single-cell data to identify targets before feeding them into the Origin molecule-design platform; management said the technology has already suggested additional prolactin-related indications.
• The company remains dependent on unproven clinical and commercial assumptions: durability of hair regrowth will not be established by the 13- or 26-week readouts, and the cited market opportunities and product profile are based partly on modeling, consumer research, and hypothetical profiles rather than clinical efficacy results.

Absci Price Performance

ABSI traded down $0.21 during trading on Wednesday, hitting $9.20. The stock had a trading volume of 1,336,700 shares, compared to its average volume of 4,518,850. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -11.09 and a beta of 2.35. The company has a 50 day moving average price of $8.68 and a 200-day moving average price of $5.38. Absci has a one year low of $2.24 and a one year high of $12.06.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Absci in a report on Wednesday. Morgan Stanley reiterated a “positive” rating and issued a $10.00 price target on shares of Absci in a research note on Thursday, June 25th. Wall Street Zen downgraded shares of Absci from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Truist Financial boosted their price objective on shares of Absci from $11.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Finally, Leerink Partners began coverage on shares of Absci in a report on Thursday, June 4th. They issued an “outperform” rating and a $12.00 target price on the stock. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Absci presently has a consensus rating of “Moderate Buy” and an average price target of $13.43.

Institutional Investors Weigh In On Absci

Large investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Absci in the third quarter worth about $26,000. BNP Paribas Financial Markets increased its position in Absci by 91.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company’s stock worth $29,000 after purchasing an additional 5,385 shares in the last quarter. Legal & General Group Plc increased its position in Absci by 45.9% during the 2nd quarter. Legal & General Group Plc now owns 11,690 shares of the company’s stock worth $30,000 after purchasing an additional 3,678 shares in the last quarter. Scientech Research LLC bought a new position in Absci in the 3rd quarter valued at approximately $31,000. Finally, Russell Investments Group Ltd. boosted its position in Absci by 13,965.9% in the third quarter. Russell Investments Group Ltd. now owns 11,534 shares of the company’s stock valued at $35,000 after buying an additional 11,452 shares in the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Key Headlines Impacting Absci

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Absci announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, providing a potential clinical catalyst for the company’s AI-designed therapeutics pipeline. The company also said its cash, cash equivalents and marketable securities should fund operations into the second half of 2028. Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and raised or maintained a $13.00 price target, implying approximately 43.6% potential upside based on the referenced price. Benzinga analyst rating report
• Positive Sentiment: Needham & Company reaffirmed its Buy rating with an $11.00 price target, representing approximately 21.5% potential upside. The repeated bullish analyst views may support sentiment toward ABSI. Benzinga analyst rating report
• Positive Sentiment: Absci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly. The financing strengthens liquidity and extends the company’s operating runway, while Lilly’s participation may add strategic validation. Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Reported short interest was listed as zero shares with zero days to cover, offering no meaningful indication of short-covering demand or bearish positioning. The data may be incomplete or unreliable.
• Negative Sentiment: Second-quarter results missed expectations: adjusted loss was $0.21 per share versus the $0.19 consensus estimate, while revenue of $0.32 million fell well short of the $0.89 million forecast. Absci remains deeply unprofitable, creating a fundamental counterweight to the clinical and financing news. Absci second-quarter earnings report

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.